Tricuspid Regurgitation
Conditions
Brief summary
This study is to evaluate the safety and technical performance of the Cardiovalve Transfemoral System for tricuspid valve replacement. Data collected in the clinical study will include 30-day safety and performance of the device and delivery system, and long-term clinical outcomes over a follow-up of 5 years.
Detailed description
The Cardiovalve Transfemoral System for tricuspid valve replacement Data collected in the clinical study will include 30-day safety and performance of the device and delivery system, and long-term clinical outcomes over a follow-up of 5 years.
Interventions
DEVICECardiovalve Transfemoral Tricuspid Valve
The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
Sponsors
Cardiovalve Ltd.
Cardiovascular Research Foundation, New York
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 84 Years
Healthy volunteers
No
Inclusion criteria
1. Participant is 85 ≥ Age ≥ 18 years 2. Participant has severe, symptomatic tricuspid regurgitation (TR) ≥ 3+ based upon echocardiography, as assessed by Independent core laboratory 3. Participant is New York Heart Association (NYHA) Class II-IVa 4. Participant has left ventricular ejection fraction (LVEF) ≥ 35% 5. Participant distance of 6 minute walk test (6MWT) ≥ 60 m 6. Participant adequately treated based upon medical standards, including for coronary artery disease, mitral regurgitation and Guideline Directed Medical Therapy (GDMT) for heart failure for at least 30-days prior to index procedure. 7. Acceptable by the site "Heart Team" including an interventional cardiologist, cardiothoracic surgeon, heart failure cardiologist and recommended as a candidate for the Cardiovalve System 8. Participant approved by the Subject Screening Committee
Exclusion criteria
1. Known significant intracardiac shunt (e.g. septal defect) or congenital structural heart disease (PFO's without significant shunts are allowed) 2. Significant coronary artery disease requiring treatment 3. Primary tricuspid disease (e.g. rheumatic, myxomatous degeneration, tricuspid valve prolapse) 4. Severe right ventricular failure per ASE guidelines1 5. Systolic pulmonary arterial pressure \> 65 mmHg as assessed by transthoracic echocardiography 6. Presence of any known life threatening non-cardiac disease that will limit the subject's life expectancy to less than one year 7. Cerebrovascular event (stroke, TIA) within the past 3 months 8. Active endocarditis or history of mitral/tricuspid endocarditis within the last 12 months 9. Patient has significant left sided valvular heart disease which requires treatment (e.g. mitral regurgitation or stenosis, and aortic regurgitation or stenosis) 10. Documented primary coagulopathy or platelet disorder, including thrombocytopenia (absolute platelet count \<90k) 11. Documented evidence of significant renal dysfunction (eGFR\<30 ml/min/1.73m2) or on any form of dialysis at time of screening within the last 4 weeks 12. Contraindication or known allergy to device's components, to anti-coagulation therapy with vitamin K antagonists or to contrast media that cannot be adequately premedicated 13. Patients unsuitable for implantation because of thrombosis of the lower venous system or presence of a vena cava filter 14. The patient has contraindication against a transesophageal echo (TEE) during the procedure 15. Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days) 16. Hepatic insufficiency (MELD \> 10) 17. Female patient of child-bearing potential 18. Psychiatric or behavioral disease including known alcohol or drug abuser that is likely to impair compliance with protocol 19. Requirement for Antibiotic Treatment within the last 48 hours 20. Cardiac Anatomy deemed not suitable for the Cardiovalve Implant 21. Surgical or interventional procedure planned within 30 days prior to index procedure 22. UNOS Status 1 heart transplant or prior orthotropic heart transplantation. 23. Any prior Tricuspid valve surgery or transcatheter Tricuspid valve procedure 24. Modified Rankin Scale \> 4 disability 25. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within one month prior to index procedure 26. Need for any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of index procedure 27. Currently participating in an investigational drug or another device study which has not reached its primary endpoint 28. Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment 29. Chronic oral steroid or other condition that could impair healing response (e.g. cardiac sarcoidosis or other chronic inflammatory disease). 30. Acutely decompensated heart failure (i.e. hemodynamically unstable or requiring IV inotrope ) at the time of screening 31. Severe COPD or continuous use of home oxygen 32. Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study 33. Aortic or pulmonic valve disease requiring surgery 34. Venous peripheral anatomy unsuitable for implant delivery 35. Chronic anemia (Hgb \< 9)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Primary Safety Endpoint (Patient Based) Participants Implanted without Major Device Related Adverse Events through thirty days | 30 Days | The ability of the Cardiovalve to be implanted without Major Device Related Adverse Events through thirty (30) days including: I Death (Cardiovascular mortality vs non-cardiovascular); II Reintervention (operative or transcatheter) due to progressive or recurrent TR or device related complications; III Disabling stroke; IV Myocardial infarction (MVARC definition); V Major access site and vascular complications; VI Fatal or life-threatening bleeding (MVARC Type III-V); VII Arrhythmia and conduction disorder requiring permanent pacing; VIII Right coronary artery occlusion requiring intervention; IX Cardiac tamponade, X Renal failure requiring dialysis |
| 1. Primary Performance Endpoint - Technical Success of Cardiovalve Delivery and Function in each participant | 30 Days | Cardiovalve Technical Success defined as: I Successful access, delivery and retrieval of the delivery system; II Successful deployment of correct positioning of the first intended implant; III Freedom from emergency surgery or reintervention related to the device or access procedure without any procedural mortality, stroke, and device dysfunction at 30-day follow-up. |
| Primary Performance Endpoint - Clinical Performance - Reduction in Tricuspid Regurgitation severity measured using Echocardiography and compared to baseline | 30 Days | Cardiovalve Clinical Performance will be evaluated as: I The reduction in degree of tricuspid regurgitation measured immediately after the procedure compared to baseline; II The reduction in degree of tricuspid regurgitation measured at the time of discharge or 7 days post procedure, whichever comes first, in comparison with baseline Tricuspid Regurgitation is measured using Echocardiography and is graded based on degree of severity using grading conventions from 0 to 4+. 0 = absent 1. = mild 2. = moderate 3. = moderate to severe 4. = severe |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Secondary Performance Endpoint - Unrestricted Movement of Cusps | 30 days, 3 months, 6 months | Unrestricted Movement of Cusps: the percentage of medical devices with unrestricted movement of cusps after implantation as assessed with echocardiography |
| Secondary Performance Endpoint - New York Heart Association (NYHA) functional class | 30 days, 3 months, 6 months | NYHA function class I - IV; Higher functional class represents more severe symptoms of heart failure NYHA Classification - The Stages of Heart Failure: 1. Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. 2. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. 3. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest. 4. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. |
| Secondary Performance Endpoint - Kansas City Cardiomyopathy Questionnaire | 30 days, 3 months, 6 months | Kansas City Cardiomyopathy Questionnaire (KCCQ) - 23 subjective quality of life questions. Assessed before and after implantation. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. There are 3 subscales: Symptom Burden - range 0-100; Physical Limitation - range 0-100; Quality of Life - range 0-100; The total KCCQ score represents the mean (average) of the three subscale scores. |
| Secondary Performance Endpoint - 6 minute walk test | 30 days, 3 months, 6 months | 6 minute walk test distance (meters) |
| Secondary Performance Endpoint - Tricuspid Regurgitation Severity | 30 days, 3 months, 6 months | Tricuspid Regurgitation is measured using Echocardiography and is graded based on degree of severity using grading conventions from 0 to 4+. 0 = absent 1. = mild 2. = moderate 3. = moderate to severe 4. = severe |
| Secondary Performance Endpoint - Cusp Insufficiency | 30 days, 3 months, 6 months | Cusp Insufficiency: Change in the degree of the cusp insufficiency as assessed with echocardiography (ordinal) from a higher to a lower value |
Countries
United States
Outcome results
None listed